Sabrina Lusvarghi, Ph.D.
Affiliations: | 2009 | Carnegie Mellon University, Pittsburgh, PA |
Area:
Organic Chemistry, BiochemistryGoogle:
"Sabrina Lusvarghi"Mean distance: (not calculated yet)
Parents
Sign in to add mentorBruce A. Armitage | grad student | 2009 | Carnegie Mellon | |
(From molecules to organisms: Molecular recognition using proteins, peptides and peptide nucleic acids.) |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Yang Y, Wu ZX, Wang JQ, et al. (2021) OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance. Frontiers in Pharmacology. 12: 620874 |
Kita DH, Guragossian N, Zattoni IF, et al. (2021) Mechanistic basis of breast cancer resistance protein inhibition by new indeno[1,2-b]indoles. Scientific Reports. 11: 1788 |
Sajid A, Lusvarghi S, Murakami M, et al. (2020) Reversing the direction of drug transport mediated by the human multidrug transporter P-glycoprotein. Proceedings of the National Academy of Sciences of the United States of America |
Ashar YV, Zhou J, Gupta P, et al. (2020) BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. Cancers. 12 |
Wu CP, Hung CY, Lusvarghi S, et al. (2020) Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochemical Pharmacology. 114137 |
Yang Y, Ji N, Teng QX, et al. (2020) Sitravatinib, a Tyrosine Kinase Inhibitor, Inhibits the Transport Function of ABCG2 and Restores Sensitivity to Chemotherapy-Resistant Cancer Cells . Frontiers in Oncology. 10: 700 |
Wu CP, Lusvarghi S, Hsiao SH, et al. (2020) Licochalcone A Selectively Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Drugs. Journal of Natural Products |
Wu CP, Lusvarghi S, Tseng PJ, et al. (2020) MY-5445, a phosphodiesterase type 5 inhibitor, resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to cytotoxic anticancer drugs. American Journal of Cancer Research. 10: 164-178 |
Lusvarghi S, Robey RW, Gottesman MM, et al. (2020) Multidrug transporters: recent insights from cryo-electron microscopy-derived atomic structures and animal models. F1000research. 9 |
Wu ZX, Yang Y, Teng QX, et al. (2020) Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers. 12 |